InnoCan Pharma Corporation INNPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 23.53M | 25.28M | 26.61M | 27.03M | 28.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.53M | 25.28M | 26.61M | 27.03M | 28.83M |
| Cost of Revenue | 2.25M | 2.58M | 2.68M | 3.12M | 3.33M |
| Gross Profit | 21.28M | 22.71M | 23.93M | 23.91M | 25.50M |
| SG&A Expenses | 23.96M | 24.30M | 24.25M | 24.07M | 24.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.96M | 27.81M | 27.87M | 28.28M | 28.51M |
| Operating Income | -3.43M | -2.53M | -1.26M | -1.25M | 318.00K |
| Income Before Tax | -875.00K | -770.00K | 85.00K | -1.51M | 629.00K |
| Income Tax Expenses | -42.00K | 228.00K | 426.00K | 739.00K | 937.00K |
| Earnings from Continuing Operations | -0.83 | -1.00 | -0.34 | -2.24 | -0.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -125.00K | -516.00K | -783.00K | -989.00K | -1.27M |
| Net Income | -958.00K | -1.51M | -1.12M | -3.23M | -1.58M |
| EBIT | -3.43M | -2.53M | -1.26M | -1.25M | 318.00K |
| EBITDA | -3.40M | -2.49M | -1.21M | -1.22M | 352.00K |
| EPS Basic | -0.21 | -0.33 | -0.25 | -0.72 | -0.35 |
| Normalized Basic EPS | -0.20 | -0.27 | -0.12 | -0.31 | -0.09 |
| EPS Diluted | -0.21 | -0.33 | -0.25 | -0.72 | -0.35 |
| Normalized Diluted EPS | -0.20 | -0.27 | -0.12 | -0.31 | -0.09 |
| Average Basic Shares Outstanding | 17.98M | 17.97M | 17.94M | 17.88M | 17.71M |
| Average Diluted Shares Outstanding | 17.98M | 17.97M | 17.94M | 17.88M | 17.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |